March 18, 2005

Dear Pharmacy Provider,

Please be aware that prescribers of Plavix\textsuperscript{\textregistered} may begin writing “Stent” on their prescriptions. If you see this on the face of a valid prescription you may enter it in the diagnosis field of the prior authorization form and send the completed form in for prior authorization review without sending the form to the prescriber.

Effective March 28, 2005, the Oklahoma Health Care Authority will implement additional screening of point-of-sale claims through the Prospective Drug Utilization Review (ProDUR) process.

As a reminder, for claims which are suspended, once the pharmacist has verified that the claim should be dispensed to the client, the alert can be overridden at the pharmacy level. To override or respond to a suspended claim, please enter the following information in the DUR Response fields (based on type of alert received):

1. The appropriate DUR Conflict Code:
   - PA - Drug-Age Precautions,
   - DD - Drug-Drug Interactions,
   - MC - Drug-Disease Interactions,
   - PG - Drug Pregnancy Precautions, etc.

2. The appropriate DUR Intervention Code which reflects how the pharmacist determined the claim should be handled: M0 – Physician consulted, R0 – Pharmacist consulted, or P0 - Patient consulted.

3. The appropriate DUR Outcome Code based on the result of the above intervention. For example: 1B – Filled prescription as is, 1G – Filled, with prescriber approval, 2A – Prescription not filled, etc.

Please contact the pharmacy help desk if you have questions regarding the changes to the ProDUR screening process.

The following quantity limits are being implemented April 1, 2005 to insure that prescription claims are submitted to Oklahoma Medicaid using industry standard billing units. The use of standard billing units decreases overpayment of pharmacy claims, auditing and recoupment processes, and federal drug rebate disputes. The standard billing units are developed by the National Council for Prescription Drug Programs (NCPDP). The NCPDP version 5.1 code set is required for all pharmacy transactions to maintain HIPAA compliance.

- Darbopoetin alfa (Aranesp) 4 doses for 28 days
- Anakinra (Kineret) 28 doses for 28 days
- Enoxaparin (Lovenox) 60 doses for 30 days
- Fondaparinux (Arixtra) 30 doses for 30 days
- Filgrastim (Neupogen) 30 doses for 30 days
- Glatiramer (Copaxone) 30 doses for 30 days
- Interferon beta-1a (Rebif) 12 doses for 30 days
- Dalteparin (Fragmin) 30 doses for 30 days
- Triamcinolone injection 10 mls for 7 days
- Lindane shampoo and lotion 60 mls for 7 days

Thank you for your continued service to Oklahoma’s Medicaid clients.